-+ 0.00%
-+ 0.00%
-+ 0.00%

Praxis Precision Medicines makes equity investment in Remagine Labs

PUBT·07/07/2026 12:03:03
Listen to the news
Praxis Precision Medicines makes equity investment in Remagine Labs
  • Praxis Precision Medicines made an equity investment in Remagine Labs to accelerate a collaboration on transdermal ulixacaltamide for essential tremor.
  • The deal supports development of an iontophoretic patch, positioning ulixacaltamide beyond the company’s oral program.
  • Ulixacaltamide’s essential tremor NDA is under FDA review, with a PDUFA target action date of Jan. 29, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070800PRIMZONEFULLFEED9757768) on July 07, 2026, and is solely responsible for the information contained therein.